Global Antibody Discovery Services and Platforms Market, 2018-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028” report has been added to ResearchAndMarkets.com’s offering.
The Antibody Discovery: Services and Platforms (2nd Edition), 2018-2028′ report provides an extensive study on the current market landscape and future outlook of companies offering antibody discovery services and platforms.
Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class of biologics, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages.
It is worth mentioning that the research and development efforts associated with antibody-based therapeutics have significantly paced up in 2017; this momentum is projected to continue over the coming several years. In fact, in 2017, more than 10 monoclonal antibodies were approved by the FDA and EMA. Additionally, close to 20 monoclonal antibodies are currently being evaluated in late stages of clinical development. In addition to monoclonal antibodies, other novel antibody-based therapeutics, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, are steadily gaining traction.
The discovery of antibodies is a long, arduous and cost intensive process. As a result, many biopharmaceutical developers are opting to outsource such operations. Modern contract research organizations (CROs), offering antibody discovery services, claim to have novel and advanced technologies to support players developing antibody-based products in their early stage research requirements.
Additionally, there are a number of companies that have developed proprietary antibody discovery platforms and have made them available to drug developers. In-licensing the technology of such players for use in drug discovery operations is considered a viable business strategy, offering both time and cost related benefits to drug / therapy developers. As the demand for such therapeutic / diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to grow in the foreseen future.One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. We have provided insights on the likely evolution of the market in different regions, including North America, Europe, China and the rest of the world. In addition, we have provided the likely distribution of the opportunity across the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), and the nature of antibody generated (chimeric, humanized and fully human).In addition, we have estimated the future opportunity for platform providers in term of the likely licensing deal structures and the agreements that are expected to be signed in the foreseen future. The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain.The major share (over 80%) of revenues is anticipated to be distributed between North America and Europe; however, we believe that certain Asian countries, such as China, are likely to grow at faster rate (CAGR of 8.8%) as compared to other regions over the coming decade; this is attributed to the availability of skilled manpower, lower labor costs and a less stringent regulatory environment.The sustained growth is also expected to result in lucrative monetizing opportunities for platform providers as they compete for a share within the USD 3 billion licensing deal revenues over the coming decade (in the form of upfront and milestone payments).
The report features detailed transcripts of interviews held with the following industry stakeholders:Aaron Sato (Chief Scientific Officer, LakePharma)Christel Iffland (Vice President, Ligand Pharmaceuticals)Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)Debra Valsamis (Business Development Associate, Antibody Solutions)Garren Hilow (Co-Founder and Chief Executive Officer, Abveris)Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)Ignacio Pino (President and Chief Executive Officer, CDI Laboratories)Jeng Her (Chief Executive Officer, AP Biosciences)Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)Nalini Ghag- Motwani (President and Founding Chief Scientist, BioSavita)Sanjiban K Banerjee (Director, AbGenics Life Sciences)Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
Key Topics Covered:
2. Executive Summary
4. Antibody Discovery Process And Methods
5. Competitive Landscape
6. Benchmark Analysis
7. Comparative Analysis Of Service Providers
8. Company Profiles: Antibody Discovery Service Providers
9. Competitiveness Analysis Of Antibody Discovery Platforms
10. Company Profiles: Antibody Discovery Platform Providers
11. Partnerships And Collaborations
12. Funding And Investment Analysis
13. Opportunity Analysis
14. Case In Point: Drug Discovery Processes Of Top Selling Antibodies
15. Case Study: Antibody Humanization And Affinity Maturation
16. Future Growth Opportunities In Antibody Discovery
17. Survey Insights
18. Interview Transcripts
19. Appendix 1: Tabulated Data
20. Appendix 2: List Of Companies And OrganizationsFor more information about this report visit https://www.researchandmarkets.com/research/rsf9j2/global_antibody?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005351/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 07:14 AM/DISC: 09/19/2018 07:13 AM